Table 3. Clinical characteristics: verification cohort (CR only).
| Variable | Categories | DFS Less than 1 year n = 24 | DFS 1 year or greater n = 15 | All CR n = 39 | P |
| Age (years) | Median | 65.5 | 69 | 68 | 0.455 |
| Range | 60–79 | 62–78 | 60–79 | ||
| Sex | Male | 11 | 3 | 14 | 0.019 |
| Female | 13 | 12 | 25 | ||
| Cytogenetics* | Favorable | 1 | 1 | 2 | 0.015 |
| Intermediate/Missing | 18 | 14 | 32 | ||
| Unfavorable | 5 | 0 | 5 | ||
| Race | White | 23 | 15 | 38 | 0.231 |
| Black | 1 | 0 | 1 | ||
| Secondary AML | De novo | 19 | 11 | 30 | 0.112 |
| Secondary | 4 | 4 | 8 | ||
| RAEB-t | 1 | 0 | 1 | ||
| RAEB | 0 | 0 | 0 | ||
| WBC | 30 000 or less | 15 | 11 | 26 | 0.592 |
| Greater than 30 000 | 9 | 4 | 13 | ||
| Median (×10∧3) | 15.05 | 9.0 | 14.65 | 0.254 | |
| Range (×10∧3) | 1.6–97.7 | 1.4–53.6 | 1.4–97.7 | ||
| NPM1 mutated | Yes | 12 | 6 | 18 | 0.982 |
| No | 12 | 9 | 21 | ||
| FLT3 ITD mutated | Yes | 8 | 2 | 10 | 0.200 |
| No | 16 | 13 | 29 |
Modeling of DFS was performed only among patients who achieved CR to induction therapy. Each of the clinical co-variates, demographic characteristics and molecular characterics was tested for association with DFS using logrank test.
Logrank test was applied to compute p-values.
*
Cytogenetics was coded as continuous variable: Favorable = 1, Intermediate/Unknown = 2, Unfavorable = 3.
DFS indicates disease free survival; CR, complete responder; WBC, white blood cell; NPM1 nucleophosmin 1; RAEB-t, refractory anemia with excess blasts in transformation; and RAEB, refractory anemia with excess blasts.